세계의 CAR-T 세포 치료 시장 : 시장 규모, 점유율, 동향 - 제품별, 표적 항원별, 적응증별, 인구통계별, 최종 사용자별, 지역별 예측(-2029년)

The global CAR T-cell therapy market is estimated to reach USD 29.0 Billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 39.6% during the forecast period of 2024 to 2029. Market growth is driven by the rise in the global cancer prevalence. Technological advancements in CAR T-cell therapies and rising therapy development investment and funding is likely to propel the market growth. However, adverse effects associated with CAR T-cell therapy and high treatment costs are some of the major factors expected to restrain the market growth during the forecast period.

"Yescarta segment accounted for the highest share of 2023."

Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment held the largest market share in 2023. Market growth is attributed to high response rates and durable remissions of Yescarta in treating relapsed/refractory cancers leading to an increase in therapy adoption.

"The Hospitals End User segment held the dominant share in the CAR T-cell therapy market."

Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long term care facilities and specialty centers. In 2023, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period. Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell treatments as more hospitals embrace these therapies. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborations with pharmaceutical companies, hospitals contribute to expanding the evidence base and accelerating regulatory approvals, which in turn stimulates market growth.

"Asia Pacific region estimated to show fastest growth rate."

The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. During the forecast period, Asia Pacific region is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in the Asia Pacific market. In addition, increasing collaborations between hospitals, universities, and industries in Chinaare expected to provide lucrative market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific's progress in developing and validating CAR T-cell treatments, positioning the region as a key player in advancing therapeutic outcomes in oncology in CAR T-cell therapy.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70%, and Demand Side - 30%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%

List of Companies Profiled in the Report:

• Bristol-Myers Squibb Company (US)
• Gilead Sciences Inc. (US)
• Novartis AG (Switzerland)
• Johnson & Johnson (US)
• CARsgen Therapeutics Holdings Limited (China)
• IASO Biotherapeutics (China)
• JW (Cayman) Therapeutics Co. Ltd (China)
• ImmunoAct (India)
• CRISPR Therapeutics (Switzerland)
• Autolus Therapeutics (UK)
• Allogene Therapeutics (US)
• Cartesian Therapeutics Inc. (US)
• Guangzhou Bio-gene Technology Co. Ltd (China)
• Wugen (US).

Research Coverage:

This report provides a detailed picture of the CAR T-cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as product, target, demographic, indications, end-users and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (technological advancements in CAR T-cell therapies, growing cancer prevalence, and rising investment and funding for therapy development), restraints (high therapy costs and adverse effects), opportunities (expansion into solid tumors and collaborations and partnerships) and challenges (patient recruitment for trials and reimbursement issues) are influencing the growth of CAR T-cell therapy market.
• Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the CAR T-cell therapy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 REGIONS COVERED
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
  • 2.1.3 BREAKDOWN OF PRIMARIES
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 2.3 GROWTH RATE ASSUMPTIONS
  • 2.3.1 CAGR PROJECTIONS
  • 2.3.2 IMPACT OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
• 2.4 VOLUME ESTIMATION
• 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.6 RESEARCH LIMITATIONS
• 2.7 STUDY ASSUMPTIONS
• 2.8 RISK ANALYSIS
• 2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CAR T-CELL THERAPY MARKET OVERVIEW
• 4.2 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT AND COUNTRY (2023)
• 4.3 CAR T-CELL THERAPY MARKET SHARE, BY PRODUCT
• 4.4 CAR T-CELL THERAPY MARKET, BY END USER

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing cancer prevalence
    • 5.2.1.2 Technological advancements in CAR T-cell therapies
    • 5.2.1.3 Rising investment and funding for therapy development
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High therapy costs
    • 5.2.2.2 Adverse effects
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Expansion into solid tumors
    • 5.2.3.2 Collaborations and partnerships
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Patient recruitment for trials
    • 5.2.4.2 Reimbursement issues
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 PRODUCTS
  • 5.5.2 END USERS
  • 5.5.3 REGULATORY BODIES
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 CAR DESIGN AND OPTIMIZATION
    • 5.6.1.2 VIRAL VECTOR TECHNOLOGY
    • 5.6.1.3 CELL CULTURE AND EXPANSION TECHNIQUES
  • 5.6.2 COMPLIMENTARY TECHNOLOGIES
    • 5.6.2.1 GENE EDITING TECHNOLOGY (CRISPR-CAS9-BASED GENOME EDITING)
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 MONITORING AND IMAGING TECHNOLOGIES
• 5.7 PATENT ANALYSIS
  • 5.7.1 METHODOLOGY
  • 5.7.2 NUMBER OF PATENTS FILED
  • 5.7.3 INNOVATION AND PATENT APPLICATIONS
  • 5.7.4 TOP APPLICANTS
• 5.8 PRICING ANALYSIS
  • 5.8.1 AVERAGE SELLING PRICE, BY TYPE
  • 5.8.2 AVERAGE SELLING PRICE, BY REGION
  • 5.8.3 AVERAGE SELLING PRICE TREND, BY PRODUCT
• 5.9 KEY CONFERENCES & EVENTS, 2024-2O25
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY SCENARIO
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 INVESTMENT & FUNDING SCENARIO
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12.2 BARGAINING POWER OF SUPPLIERS
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 THREAT OF SUBSTITUTES
  • 5.12.5 THREAT OF NEW ENTRANTS
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY BUYING CRITERIA

6 CAR T-CELL THERAPY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 YESCARTA
  • 6.2.1 INCREASING REACH TO DRIVE MARKET
• 6.3 KYMRIAH
  • 6.3.1 APPROVAL FOR PEDIATRIC USE TO SUPPORT MARKET GROWTH
• 6.4 CARVYKTI
  • 6.4.1 WIDESPREAD REACH TO ENSURE MARKET GROWTH
• 6.5 ABECMA
  • 6.5.1 RISING RESEARCH FOR ALTERNATIVE INDICATIONS TO DRIVE MARKET
• 6.6 TECARTUS
  • 6.6.1 GROWING FOCUS ON PATIENT-CENTRIC REIMBURSEMENT TO PROPEL MARKET
• 6.7 BREYANZI
  • 6.7.1 MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH
• 6.8 OTHER PRODUCTS

7 CAR T-CELL THERAPY MARKET, BY TARGET

• 7.1 INTRODUCTION
• 7.2 CD19
  • 7.2.1 RISING INDICATIONS IN PIPELINE TO DRIVE MARKET
• 7.3 BCMA
  • 7.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPY TO PROPEL MARKET GROWTH
• 7.4 OTHER TARGETS

8 CAR T-CELL THERAPY MARKET, BY INDICATION

• 8.1 INTRODUCTION
• 8.2 MULTIPLE MYELOMA
  • 8.2.1 RISING INCIDENCE OF MULTIPLE MYELOMA TO DRIVE MARKET
• 8.3 B-CELL LYMPHOMA
  • 8.3.1 RISING PREVALENCE TO PROPEL MARKET GROWTH
• 8.4 ACUTE LYMPHOBLASTIC LEUKEMIA
  • 8.4.1 FOCUS ON AFFORDABLE CAR T-CELL THERAPIES TO DRIVE MARKET
• 8.5 OTHER INDICATIONS

9 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC

• 9.1 INTRODUCTION
• 9.2 ADULTS
  • 9.2.1 INCREASING NUMBER OF LYMPHOMAS TO DRIVE MARKET
• 9.3 PEDIATRICS
  • 9.3.1 RISING PREVALENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH

10 CAR T-CELL THERAPY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 GROWING PREVALENCE OF CANCER TO DRIVE MARKET
• 10.3 SPECIALTY CENTERS
  • 10.3.1 GROWING RESEARCH COLLABORATIONS TO PROPEL MARKET
• 10.4 LONG-TERM CARE FACILITIES
  • 10.4.1 GROWING CASES OF CHRONIC DISORDERS TO DRIVE MARKET

11 CAR T-CELL THERAPY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: RECESSION IMPACT
  • 11.2.2 US
    • 11.2.2.1 Rising R&D activities for CAR T-cell therapies to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Government initiatives for regenerative medicine research to drive market
• 11.3 EUROPE
  • 11.3.1 EUROPE: RECESSION IMPACT
  • 11.3.2 GERMANY
    • 11.3.2.1 Rising focus on clinical research to drive market
  • 11.3.3 UK
    • 11.3.3.1 Rising technological advancements in automation to drive market
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand
  • 11.3.5 ITALY
    • 11.3.5.1 Growth in biotech sector to drive market
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising focus on cell therapies to support market growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
  • 11.4.2 CHINA
    • 11.4.2.1 Rising number of CAR T-cell clinical trials to support market growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing product approvals to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Robust infrastructure for clinical trials and well-developed healthcare sector to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Rising growth in biopharmaceutical industry to drive market
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: RECESSION IMPACT
  • 11.5.2 BRAZIL
    • 11.5.2.1 High expenditure on healthcare to support market growth
  • 11.5.3 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MEA TO GROW AT SLOWER PACE DURING FORECAST PERIOD
  • 11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL THERAPY MARKET
• 12.3 REVENUE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
  • 12.4.1 RANKING OF KEY MARKET PLAYERS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Product footprint
    • 12.5.5.3 Target footprint
    • 12.5.5.4 Indication footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS
  • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 BRISTOL-MYERS SQUIBB COMPANY
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
      • 13.1.1.3.2 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 GILEAD SCIENCES, INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product approvals
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Other developments
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 NOVARTIS AG
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches & approvals
      • 13.1.3.3.2 Expansions
      • 13.1.3.3.3 Other developments
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 JOHNSON & JOHNSON
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product approvals
      • 13.1.4.3.2 Deals
  • 13.1.5 JW (CAYMAN) THERAPEUTICS CO. LTD.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product approvals
      • 13.1.5.3.2 Deals
  • 13.1.6 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
      • 13.1.6.3.2 Other developments
  • 13.1.7 CARSGEN THERAPEUTICS HOLDINGS LIMITED
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product approvals
      • 13.1.7.3.2 Deals
      • 13.1.7.3.3 Expansions
  • 13.1.8 IASO BIOTHERAPEUTICS
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product approvals
      • 13.1.8.3.2 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD (HEDY GROUP CO., LTD.)
  • 13.2.2 CARTESIAN THERAPEUTICS, INC.
  • 13.2.3 AUTOLUS THERAPEUTICS
  • 13.2.4 ALLOGENE THERAPEUTICS
  • 13.2.5 CRISPR THERAPEUTICS
  • 13.2.6 WUGEN

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS